Optomed USA, Inc. Announces Sponsorship to the Association of Schools and Colleges of Optometry (ASCO)

Optomed Sponsors ASCO

 Optomed USA, Inc. is pleased to announce the sponsorship to The Association of Schools and Colleges of Optometry (ASCO), the academic leadership organization committed to advancing optometric education and research to enhance the health and well-being of the public. "Optomed is excited to support the wide range of programs including teaching clinics and outreach programs with students, faculty, and leadership," said Jean-Christophe Firer, President & CEO, Optomed USA, Inc.

ASCO proudly represents all accredited schools and colleges of optometry in the United States. Optomed, a Finnish medical technology company is one of the leading providers of handheld fundus cameras worldwide. Their Optomed Aurora IQ camera is portable, has a 50 degrees field of view with non-mydriatic operation, high contrast optical design with autofocus and autoexposure, and has cloud and ERM connectivity. Their camera can be integrated with AI technology to easily scan and detect retinal diseases such as diabetic retinopathy, AMD, and glaucoma. Optomed's mission to help save the vision of millions of people.


Jean-Christophe Firer, President & CEO 844-474-4481 jc.firer@optomed.com

About Optomed

Optomed Plc is a Finnish medical technology company and one of the leading providers of handheld fundus cameras worldwide. Optomed Plc combines handheld screening devices with software and optional artificial intelligence integration with the aim to transform the diagnostic process of blinding eye diseases such as rapidly increasing diabetic retinopathy. In its business, Optomed Plc focuses on eye-screening devices and software solutions-related R&D in Finland and sales through different channels in over 60 countries. Optomed Plc has an extensive portfolio of over 50 international patents protecting the technology.

Forward-Looking Statements

This press release contains " forward-looking statements"  relating to future events. These statements may be identified by words such as "may," "could," "expects," "intends," "anticipates," "plans," "believes," "aims," "estimates," or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Optomed Plc and its affiliates (including Optomed USA, Inc.) may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Optomed USA, Inc. and its affiliates, including, without limitation, the global spread of COVID-19, or the Coronavirus, and the various restrictions deriving therefrom. In addition, Optomed Plc and its affiliates (including Optomed USA, Inc.) rely, and expect to continue to rely, on third parties to conduct certain activities, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Optomed Plc and its affiliates (including Optomed USA, Inc.) may experience significant delays in the conduct of their activities. Optomed Plc and its affiliates (including Optomed USA, Inc.) disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


Source: Optomed USA, Inc.

About Optomed USA Inc.

Optomed USA, Inc., a wholly owned subsidiary of Optomed Plc, a Finnish medical technology company.

Optomed USA Inc.
1153 Wenig Court
Pleasanton, CA

More Press Releases